The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

Vertex Pharmaceuticals is expected to outshine projections when it reports Q1 2025 earnings, with strong sales from its ...

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

A spokesperson told The Independent that the FDA is actively working to ensure continuity of operations during the reorganization period and remains committed to ensuring critical programs and ...

The Food and Drug Administration (FDA) is coming under fire for not publicizing its own report into an E. coli outbreak last year that spread across 15 states and infected 89 people, one of whom died.

Despite the severity of the outbreak, the Food and Drug Administration (FDA) never made a public announcement. According to an internal report, the investigation was closed quietly in February ...

On January 30th, in a landmark decision that could reshape the way acute pain is treated in the United States, the FDA approved suzetrigine (brand name, Journavx), a first-in-class non-opioid ...

After a sudden pause of steep "reciprocal" tariffs by the Trump administration (but not a pause on all tariffs instituted) on Wednesday, the index rebounded strongly. As of Thursday afternoon, it had ...

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...

The Food and Drug Administration (FDA) has approved a prefilled syringe formulation of Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.